Tuesday, May 11, 2010 6:51:06 AM
11.05.2010 12:00
China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
HAIKOU CITY, China, May 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.
First Quarter Highlights -- Revenue increased 16% to $15.1 million from $13.0 million in the first quarter of fiscal 2009 -- Gross profit grew 3% to $6.1 million from $5.9 million in the first quarter of fiscal 2009 -- Income from operations rose 19% to $4.8 million from $4.1 million in the 2009 period -- Net income climbed 17% to $4.3 million, or $0.10 per diluted share, from $3.7 million, or $0.09 per diluted share a year ago
"We are pleased to report a solid start to 2010 with healthy revenue and net income growth, in the first quarter," said China Pharma's President and CEO, Ms. Zhilin Li. "The strong revenue increase and healthy profit margins were partly driven by a continued increase in demand for our existing products and the successful launch of new products in the last twelve months. We look forward to accelerating this growth trajectory by increasing market penetration of key existing products and introducing new products to increase revenues and support a stable gross margin."
Recent CPHI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:47 PM
- China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split • PR Newswire (US) • 02/23/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:11 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:16:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/26/2024 10:04:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/12/2024 07:42:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:05:21 PM
- China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device • PR Newswire (US) • 11/29/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2023 09:05:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 08:06:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 08:06:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:40:13 PM
- China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs • PR Newswire (US) • 08/09/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM